Skip to main content

Table 1 Change in packing density of MCC (mean +/– standard deviation) at 24 h after exposure to varying concentrations of bortezomib

From: Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib

Bortezomib concentration (μM) MCC Packing Density (% nuclear area)
  HCT-8Ea HCT-8E11
0 53.2 ± 5.5 50.8 ± 3.8
0.25 50.9 ± 6.2 48.6 ± 3.2
0.50 50.2 ± 5.6 46.6 ± 4.1
1.0 44.6 ± 5.7* 42.5 ± 3.8*
2.5 45.9 ± 5.6* MCC disaggregated
  1. MCC derived from both cell lines disaggregate when treated with 5 μM of bortezomib. Packing density changes were shown to be significant after pre-treatment with 1 μM of bortezomib (p = 1.3 × 10-7 and p = 1.8 × 10-6 for HCT-8Ea and HCT-8E11 derived MCC respectively as assessed using a t-test).
  2. * p≤0.05 for comparison with control conditions.